Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Interferon beta (IFNbeta) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (M...

Full description

Bibliographic Details
Main Authors: Kaushal S Gandhi, Fiona C McKay, Eve Diefenbach, Ben Crossett, Stephen D Schibeci, Robert N Heard, Graeme J Stewart, David R Booth, Jonathan W Arthur
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2864746?pdf=render

Internet

http://europepmc.org/articles/PMC2864746?pdf=render

Similar Items